01:03 PM EDT, 09/04/2024 (MT Newswires) -- Myriad Genetics ( MYGN ) said Wednesday that it is discontinuing the analysis of hospital resource utilization and costs of patients getting GeneSight testing compared with a control group due to significant disparities between the groups.
The non-GeneSight control group was not viable for the study because of differences in baseline hospital resource utilization and costs, according to the company.
Shares of the company were down 8.6% in recent trading.
Price: 25.09, Change: -2.37, Percent Change: -8.63